Key Highlights

  • The GAAP net loss for the third quarter ended September 30, 2026 was USD 236.3 million, or USD 2.64 per share, against a loss of USD 3.5 million, or USD 0.04, a year earlier.
  • A one-time litigation settlement charge of USD 389.7 million drove the loss, of which management said USD 380.7 million is payable in cash through April 2027.
  • Product sales rose to USD 222.7 million from USD 51.7 million, and total Revenue reached USD 225.3 million versus USD 54.3 million in the prior-year quarter.
  • Management said adjusted EBITDA reached USD 140.5 million, and cash and equivalents ended September at USD 396.1 million before the settlement payments, up from USD 190.7 million at year end.

A USD 389.7 Million Charge Turns Strong Sales Into a Loss

Liquidia (NASDAQ:LQDA) filed its Quarterly Report and held its Earnings Call on November 10, 2026. Total revenue was USD 225.3 million, with YUTREPIA product sales of USD 222.7 million. Loss from operations was USD 263.5 million, against Operating Income of USD 1.8 million a year earlier, because costs included a USD 389.7 million litigation settlement, net, of which USD 19.45 million relates to a related party. An income tax benefit of USD 30.1 million narrowed the net loss to USD 236.3 million. For the nine months, net loss was USD 108.7 million, or USD 1.22 per share. The company makes YUTREPIA, an inhaled dry-powder form of treprostinil for pulmonary arterial hypertension.

What the United Therapeutics Settlement Changes for YUTREPIA

On October 13, 2026, the company settled all outstanding litigation with United Therapeutics. Under the agreement, it will stop promoting YUTREPIA for PH-ILD and amend the label to remove that indication, leaving pulmonary arterial hypertension. Management said existing PH-ILD patients are not required to switch, and said no Royalty or ongoing payments are due to United after the final settlement payment in April 2027. The charge also covers related agreements with Sandoz, Henderson and a pharmacy benefit manager, and impairments of USD 6.4 million and USD 2.7 million after the Sandoz promotion agreement ended. Service revenue, which was USD 2.6 million in the quarter, will no longer be generated.

Sales Momentum, October Referrals and Balance Sheet Strain

On the call, management said net product sales rose USD 52 million, or 31%, from the second quarter, which is a sequential figure, not a year-over-year one. Gross Margin was about 94%, Research and Development rose to USD 25.3 million, and selling, general and administrative expense fell to 26% of revenue from 33%. Management said October referral rates were more than 75% of the third-quarter daily rate and called that a floor, a view not verified here. Stockholders' Deficit was USD 25.4 million at September 30, 2026, with USD 362.7 million of settlement Liability in current liabilities, and the minimum cash covenant under a royalty financing agreement was raised to USD 45.0 million from USD 15.0 million. Management said no new Capital is needed.

Where Things Stand

The loss came from a one-time settlement charge, not from weaker sales. Liquidia (NASDAQ:LQDA) booked USD 389.7 million to resolve litigation with United Therapeutics, turning USD 222.7 million of product sales and USD 140.5 million of adjusted EBITDA, as management defined it, into a GAAP loss of USD 236.3 million. The trade-off is that the label will drop PH-ILD, cash will fall as payments run to April 2027 and Equity is negative. The material gives no formal guidance or share price reaction. Watch prescription trends after the label change, the FDA label process and the settlement payment schedule.